Compare Banco Santander SA (SAN) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Santander SA vs 10X Genomics Inc — how do they compare? Banco Santander SA trades at $13.56 (market cap $192.86B), while 10X Genomics Inc trades at $79.3 (market cap $10.07B). The key difference: Banco Santander SA is far larger — about 19.2× 10X Genomics Inc's market cap, and Banco Santander SA pays a 2.06% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Banco Santander SA for 55 Days and 10X Genomics Inc for 92 Days on average.
| SAN | TXG | |
|---|---|---|
Market Cap | $192.86B | $10.07B |
Volume | 10,644,519 | 5,657,286 |
Sector | Financials | Health |
52-Week High | $15.05 | $97.74 |
52-Week Low | $9.65 | $11.48 |
Typical Hold Time | 55 Days | 92 Days |
Enterprise Value | $360.86B | $9.59B |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Banco Santander (SAN) trades at $13.66, down 2.5% with bearish technical signals despite strong profitability metrics including 26.25% net margin and 16.07% ROE. The company completed its Webster Financial acquisition in August 2026, expanding U.S. presence while reporting record quarterly profits. Cash flow trends show recent operational challenges with negative $28.13B net cash flow in 2024, though revenue growth remains steady at $60.02B for 2025.
SAN presents a mixed outlook with strong fundamental performance offset by technical weakness. The acquisition-driven growth strategy and technological transformation support long-term value, but negative cash flows and high debt levels ($288.23B long-term debt) pose execution risks. Analyst consensus remains moderately bullish with 64% buy ratings, suggesting potential upside if operational efficiency improves.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
